AACR Annual Meeting 2019


On Friday, March 29, 2019, a program of Educational Sessions and Methods Workshops will be presented beginning at 3 p.m. The Opening Ceremony and the Opening Plenary Session will take place on Sunday morning, March 31. The meeting will conclude at 1:30 p.m. on Wednesday, April 3. The 2019 Program in Progress follows.

Plenary Sessions    

Sunday, March 31, 2019
Opening Plenary
Chair: John D. Carpten, USC Keck School of Medicine, Los Angeles, California

Alan Ashworth, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania

Crystal L. Mackall, Stanford University School of Medicine, Stanford, California

David B. Solit, Memorial Sloan Kettering Cancer Center, New York, New York

Levi A. Garraway, Eli Lilly and Company, Indianapolis, Indiana

Peter Kuhn, USC Michelson Center for Convergent Bioscience, Los Angeles, California

Jorge J. Nieva, USC Norris Comprehensive Cancer Center, Los Angeles, California

Monday, April 1, 2019
Clinical and Translational Research in Diverse Populations
Chair: Lisa A. Newman, Henry Ford Health System, Detroit, Michigan

Olusegun I. Alatise, Obafemi Awolowo University, Ile-Ife, Osun, Nigeria

Steven R. Patierno, Duke Cancer Institute, Durham, North Carolina

Bin Tean Teh, National Cancer Center Singapore, Singapore

Melissa B. Davis, Henry Ford Health System, Detroit, Michigan

Tuesday, April 2, 2019
Manipulating the Immune System in Cancer Therapy
Chair: Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, Texas

Steven A. Rosenberg, National Cancer Institute, Bethesda, Maryland

Pablo Umana, Roche Glycart AG, Schlieren, Switzerland

Judith A. Varner, UCSD Moores Cancer Center, La Jolla, California

Dung Le, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Wednesday, April 3, 2019
Pathogen-Related Cancers: Implications for Populations and Public Health
Chair: Douglas R. Lowy, National Cancer Institute, Bethesda, Maryland

Dennis Lo, The Chinese University of Hong Kong, Shatin, Hong Kong

Jean-Michel Pawlotsky, INSERM U955, Créteil, France

Alan Bernard Rickinson, Institute of Cancer and Genomic Sciences College of Medical and Dental Sciences, Birmingham, United Kingdom

Ariela Noy, Memorial Sloan Kettering Cancer Center, New York, New York

Top of page

Major Symposia  

  • Advancing Epigenetic Therapies for Solid Tumors
  • Blood Biopsy for Response Monitoring
  • Bone Marrow Sensing of Nascent Tumors: From Early Detection to Possible Therapy
  • Cancer Metastasis
  • CDK4/6: Basic Science Concept to Clinical Practice
  • The Changing Etiology of Liver Cancer: Needs for Prevention
  • Characterizing and Managing Cancer as a Complex Adaptive System
  • Circadian Rhythms and Cancer
  • Clinical Trials and Clinical Utility
  • Convergence of Artificial Intelligence, Big Data, and Prediction in Cancer
  • Diverse Populations and Cancer
  • Earlier Detection of Lung Cancer
  • Escaping Immune Surveillance
  • Evolution and Development of Resistance to Therapy
  • Genomic Instability
  • Germline-Somatic Interactions
  • Hippo Pathway Deregulation in Cancer
  • Immune Cells that Translate the Language of Microbiota and Their Role in Cancer
  • Immune Exhaustion in Cancer Therapies
  • Immunology and the Tumor Microenvironment
  • Immunology: Cell-Based Therapies
  • Mechanotransduction in the Tumor Microenvironment
  • Metabolism: The New Kid on the Block in Cancer Care
  • Metastasis: Evidence and Clinical Implications of Early Dissemination
  • Minimal Residual Disease: From Bench to Bedside
  • Multilevel Consideration of Cancer Health Disparities: Contextual Factors to Molecular Features
  • The Next Generation of Precision Cancer Medicine: Recognizing and Exploiting the Complexity
  • Obesity and Cancer: Systemic Metabolic Dysregulation Meets Cancer Cell Metabolism
  • Obesity, Inflammation, and Cancer
  • Organ-Specific Immunity
  • Prediagnostic Exposures and Tumor Mutational Signatures in Population Studies
  • Predictive Biomarkers
  • Presidential Select Symposium: Direct-to-the-Patient Cancer Research
  • Regulation and Function of TP53
  • The Role of Angiogenesis in Cancer
  • The Science of Survivorship
  • Single-Cell Analysis of Tumor Heterogeneity
  • Sirtuins, Metabolism, and Carcinogenesis
  • Systematic Elucidation of Druggable, Nononcogene Targets
  • Systems Biology and Cancer Immunology
  • Systems Epigenetics in Hormone-Driven Cancers
  • Targeting Chromatin Modifiers in Cancer
  • Transcriptional and Gene-Regulatory States: How They Relate to Lineage Origin and Plasticity in Pediatric Cancer
  • Tumor Metabolism and DNA Damage Response

Advances in Diagnostics and Therapeutics  

  • Complement Paradox in Solid Tumors
  • Cooperativity of Tumor Clones
  • Intratumoral Approaches to Immunotherapy
  • Liquid Biopsy in Brain Tumors and Metastases
  • Modeling Treatment Response in Patient-Derived Organoids
  • Molecular Imaging
  • Nonpharmacologic Approaches to Improving Survival and Patient- Reported Outcomes
  • Proton Therapy
  • Recent Progress in Boron Neutron Capture Therapy
  • Regulation of the Immune Microenvironment by Glycosylation
  • The Remarkable Utility of Proximate Biologic Samples: Molecular Detection of Endometrial Cancer
  • RNA Editing in Cancer Pathophysiology
  • Small-Molecule Protein Degraders
  • T-Cell Bispecifics: What Have We Learned about T-Cell Engagers in the Clinic?
  • Tumor Treating Fields: A Fourth Modality in Cancer Treatment
  • Vaccines

Advances in Prevention and Interception

  • Engineering Meets Biology
  • Role of Chronic Stress in the Etiology of Cancer
  • Spectrum of Premalignant and Malignant Genomic Alterations in the “Healthy” Population

Top of page

Advances in the Science of Cancer Health Disparities

  • Novel Applications of Clinical Trials Research to Studying Disparities
  • The Science of Cancer Health Disparities

Advances in Organ Site Research 

  • Advances in Brain Metastases
  • Advances in Esophageal Cancer
  • Advances in Gastric Cancer
  • Advances in Multiple Myeloma
  • Advances in Pancreatic Cancer
  • Biologic Therapy Advances in Pediatric Tumors
  • The Changing Face of Ovarian Cancer
  • Genetic Predisposition in Hematologic Malignancies
  • Genitourinary, Bladder, and Renal Cancers
  • Neuroendocrine Tumors: Genomics, Genetics, and Therapy
  • Small Cell Lung Cancer: A Glimmer of Light at the End of the Tunnel


  • B Cells in Solid Tumors: Good or Bad?
  • Challenges and Opportunities of International Consortia
  • The Changing Economics of Cancer
  • Drugging the Undruggable
  • Fighting the IL-1 Inflammatory Pathway
  • HPV-Related Cancer Elimination
  • Immuno-oncology Combination Trials: What Went Wrong?
  • Implementation Science for Evidence-Based Cancer Prevention and Early Detection Practices in Defined Diverse Populations
  • The Integration of Nanotechnologies and Bioengineering for Cancer Research
  • Radiomics: Separating the Hype from the Hope
  • Science of Survivorship: The Intersection of Survivorship and Aging
  • Updates on Atlas Development

Educational Sessions and Methods Workshops
New this year, educational programming will begin on Friday, March 29, at 3 p.m. and continue through Saturday, March 30. Each year, 60 unique sessions are included in this program, and sessions are open to all meeting registrants. Popular programming such as the Tumor Immunology and Immunotherapy for Nonimmunologists session and roundtable discussions, New Drugs on the Horizon sessions, From Chemistry to the Clinic sessions, and Clinical Trial Design workshops will once again be offered.

Policy Sessions  
Decisions made by policymakers in Washington, D.C., have a direct impact on cancer research and the progress being made against cancer in the United States and throughout the world. The AACR sponsors sessions with government leaders, academic researchers, patient advocates, and industry representatives to foster dialogue about emerging topics in science, health, and regulatory policy.

The Science and Health Policy Track includes sessions that will provide attendees with an opportunity to learn about how policy impacts science, and vice versa. Science policy sessions will examine the current political environment affecting federal funding for the U.S. NIH and NCI, including ways for scientists to get involved in advocating for robust, sustained, and predictable budget increases. Health policy sessions will explore how scientific evidence can inform policy on cancer prevention and control and what impact policies are having on patients and communities. Past health policy sessions have covered topics such as tobacco control, the Affordable Care Act, and cancer survivorship.

The Regulatory Science and Policy Track includes informative sessions designed to highlight recent regulatory developments and provide an open forum for the consideration of issues that the FDA faces as the agency seeks to accelerate the pace of approval of safe and effective treatments for cancer patients. These sessions offer an opportunity for attendees to discuss cutting-edge issues in cancer drug, biologic, and diagnostic regulation with stakeholders from academia, industry, advocacy, and government. Past regulatory science and policy topics have included:

  • Case studies of recently approved breakthrough therapies
  • Regulatory considerations for developing CAR-T therapies
  • Reference materials for next-generation sequencing (NGS)–based tests
  • Implications of site-agnostic therapy approval for drug development

Top of page